Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Quantifying local malignant adaptation in tissue-specific evolutionary trajectories by harnessing cancer's repeatability at the genetic level.

Tokutomi N, Moyret-Lalle C, Puisieux A, Sugano S, Martinez P.

Evol Appl. 2019 Mar 18;12(5):1062-1075. doi: 10.1111/eva.12781. eCollection 2019 Jun.

2.

[The catalytic subunit of the anaphase-promoting complex, APC11, is involved in CIN+ CRC progression].

Moyret-Lalle C, Drouet Y, Puisieux A.

Med Sci (Paris). 2019 Feb;35(2):118-122. doi: 10.1051/medsci/2019020. Epub 2019 Feb 18. French. No abstract available.

PMID:
30774073
3.

Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer.

Drouet Y, Treilleux I, Viari A, Léon S, Devouassoux-Shisheboran M, Voirin N, de la Fouchardière C, Manship B, Puisieux A, Lasset C, Moyret-Lalle C.

Sci Rep. 2018 May 9;8(1):7386. doi: 10.1038/s41598-018-25631-1.

4.

A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.

Morel AP, Ginestier C, Pommier RM, Cabaud O, Ruiz E, Wicinski J, Devouassoux-Shisheboran M, Combaret V, Finetti P, Chassot C, Pinatel C, Fauvet F, Saintigny P, Thomas E, Moyret-Lalle C, Lachuer J, Despras E, Jauffret JL, Bertucci F, Guitton J, Wierinckx A, Wang Q, Radosevic-Robin N, Penault-Llorca F, Cox DG, Hollande F, Ansieau S, Caramel J, Birnbaum D, Vigneron AM, Tissier A, Charafe-Jauffret E, Puisieux A.

Nat Med. 2017 May;23(5):568-578. doi: 10.1038/nm.4323. Epub 2017 Apr 10.

PMID:
28394329
5.

[Cancer cell plasticity and metastatic dissemination].

Moyret-Lalle C, Pommier R, Bouard C, Nouri E, Richard G, Puisieux A.

Med Sci (Paris). 2016 8-9;32(8-9):725-31. doi: 10.1051/medsci/20163208020. Epub 2016 Sep 12. Review. French.

6.

TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability.

Pommier RM, Gout J, Vincent DF, Alcaraz LB, Chuvin N, Arfi V, Martel S, Kaniewski B, Devailly G, Fourel G, Bernard P, Moyret-Lalle C, Ansieau S, Puisieux A, Valcourt U, Sentis S, Bartholin L.

Cancer Res. 2015 Oct 15;75(20):4335-50. doi: 10.1158/0008-5472.CAN-14-3426. Epub 2015 Aug 17.

7.

Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons" of breast cancer.

Moyret-Lalle C, Ruiz E, Puisieux A.

World J Clin Oncol. 2014 Aug 10;5(3):311-22. doi: 10.5306/wjco.v5.i3.311. Review.

8.

Complexity in the regulation of Dicer expression: Dicer variant proteins are differentially expressed in epithelial and mesenchymal breast cancer cells and decreased during EMT.

Hinkal GW, Grelier G, Puisieux A, Moyret-Lalle C.

Br J Cancer. 2011 Jan 18;104(2):387-8. doi: 10.1038/sj.bjc.6606022. Epub 2010 Nov 30. No abstract available.

9.

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.

Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C.

Br J Cancer. 2009 Aug 18;101(4):673-83. doi: 10.1038/sj.bjc.6605193.

10.

Contribution of cell culture, RNA extraction, and reverse transcription to the measurement error in quantitative reverse transcription polymerase chain reaction-based gene expression quantification.

Combes JD, Grelier G, Laversanne M, Voirin N, Chabaud S, Ecochard R, Lasset C, Moyret-Lalle C.

Anal Biochem. 2009 Oct 1;393(1):29-35. doi: 10.1016/j.ab.2009.06.010. Epub 2009 Jun 13.

PMID:
19527676
11.

[Tumour genomics: an unstable landscape].

Moyret-Lalle C, Falette N, Grelier G, Puisieux A.

Bull Cancer. 2008 Oct;95(10):923-30. doi: 10.1684/bdc.2008.0726. French.

12.

BTG2, its family and its tutor.

Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F, Puisieux A.

Bull Cancer. 2004 Jul-Aug;91(7-8):E242-53. Review.

13.

Alterations of anaphase-promoting complex genes in human colon cancer cells.

Wang Q, Moyret-Lalle C, Couzon F, Surbiguet-Clippe C, Saurin JC, Lorca T, Navarro C, Puisieux A.

Oncogene. 2003 Mar 13;22(10):1486-90.

PMID:
12629511
14.

The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene.

Duriez C, Falette N, Audoynaud C, Moyret-Lalle C, Bensaad K, Courtois S, Wang Q, Soussi T, Puisieux A.

Gene. 2002 Jan 9;282(1-2):207-14.

PMID:
11814693
15.

p53 induction prevents accumulation of aberrant transcripts in cancer cells.

Moyret-Lalle C, Duriez C, Van Kerckhove J, Gilbert C, Wang Q, Puisieux A.

Cancer Res. 2001 Jan 15;61(2):486-8.

16.

Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage.

Duriez C, Falette N, Cortes U, Moyret-Lalle C, Puisieux A.

Oncogene. 2000 May 11;19(20):2461-4.

17.

BTG gene expression in the p53-dependent and -independent cellular response to DNA damage.

Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP, Puisieux A.

Mol Carcinog. 2000 Feb;27(2):57-64.

PMID:
10657898
18.

Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function.

Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, Larsen AK, Paillerets BB, Chouaib S.

Oncogene. 1997 Dec 4;15(23):2817-26.

19.

Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway.

Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A.

Nat Genet. 1996 Dec;14(4):482-6.

PMID:
8944033
20.

Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation.

Lalle P, Moyret-Lalle C, Wang Q, Vialle JM, Navarro C, Bressac-de Paillerets B, Magaud JP, Ozturk M.

Oncogene. 1995 Jun 15;10(12):2447-54.

PMID:
7784096
21.

ras, p53 and HPV status in benign and malignant prostate tumors.

Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C.

Int J Cancer. 1995 Apr 21;64(2):124-9.

PMID:
7542226
22.

Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations.

Mazoyer S, Lalle P, Moyret-Lalle C, Marçais C, Schraub S, Frappaz D, Sobol H, Ozturk M.

Oncogene. 1994 Apr;9(4):1237-9.

PMID:
8134127

Supplemental Content

Loading ...
Support Center